Predictive Oncology Inc ( (POAI) ) has released its Q3 earnings. Here is a breakdown of the information Predictive Oncology Inc presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Predictive Oncology Inc., a company at the forefront of AI-driven drug discovery, is expanding its operations into digital asset management, leveraging the Aethir network’s ATH token to enhance AI infrastructure capabilities. In its third-quarter 2025 earnings report, Predictive Oncology highlighted its strategic shift towards a digital asset treasury strategy, which has already secured significant financial backing through private placements. The company reported holding approximately 5.70 billion ATH tokens, with a market value of $152.8 million, positioning itself as a key operator within the Aethir ecosystem.
The company’s financial performance for the third quarter of 2025 showed a net loss of $77.65 million, primarily due to a derivative liability of $74.4 million related to its new digital asset strategy. Despite the loss, Predictive Oncology’s strategic moves aim to address the growing demand for affordable AI infrastructure by monetizing AI resources through enterprise deployments. Revenue remained relatively stable compared to the previous year, while general and administrative expenses increased due to higher legal fees and stock-based compensation.
Predictive Oncology’s collaboration with Every Cure to repurpose drugs for new indications underscores its commitment to improving patient outcomes. The appointment of Shawn Matthews to the Board of Directors further strengthens the company’s leadership as it navigates its expanded business model. The company’s strategic focus on creating a Strategic Compute Reserve through ATH holdings aims to democratize AI access and meet global infrastructure needs.
Looking ahead, Predictive Oncology remains focused on leveraging its digital asset strategy to enhance its AI-driven drug discovery capabilities. The company’s management is optimistic about the potential of its new business line to generate revenue and address the bottlenecks in AI innovation, positioning Predictive Oncology as a significant player in the AI infrastructure landscape.